Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Login and Edit functionaility are currrently unavailable.
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase Inhibitor Proteins
Cyclin-Dependent Kinase Inhibitor p27
Cyclin-Dependent Kinase 4
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
p27 as Jekyll and Hyde: regulation of cell cycle and cell motility.
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility.
p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
p27 transcriptionally coregulates cJun to drive programs of tumor progression.
MicroRNA-Mediated Suppression of the TGF-ß Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cyclin Dependent Kinase 3